Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Matthew Phipps is an analyst at William Blair. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/28/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 08/30/2024 | NCNA | Buy Now | NuCana | $1.00 | — | Matthew Phipps11% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/03/2024 | AMGN | Buy Now | Amgen | $304.52 | — | Matthew Phipps11% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 12/19/2022 | NAMS | Buy Now | NewAmsterdam Pharma | $22.15 | — | Matthew Phipps11% | — | Initiates | → Outperform | Get Alert |
| 04/20/2021 | IKNA | Buy Now | Ikena Oncology | $1.33 | — | Matthew Phipps11% | — | Initiates | → Outperform | Get Alert |
| 01/17/2018 | PIRS | Buy Now | Pieris Pharmaceuticals | — | — | Matthew Phipps11% | — | Initiates | → Outperform | Get Alert |
